Andere Sprachen Takeda Pharmaceutical Company Limited Deutsche Boerse AG

Aktien

A1CWZF

US8740602052

TKDA

Realtime-Estimate Tradegate Andere Börsenplätze 15:24:36 17.06.2024			% 5 Tage	% 1. Jan.
12,2 ^EUR	+1,67 %		-2,44 %	-4,76 %

15:21	Sektor-Update: Aktien des Gesundheitswesens geben am Montag vorbörslich nach	MT
14:13	Ovid will sich von Epilepsie-Medikament distanzieren, nachdem Takeda berichtet, dass Phase 3-Endpunkte verfehlt wurden -- Pre-Bell-Aktien fallen	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Decline Premarket Monday	15:21
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell	14:59
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	14:13
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	14:00
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies	13:32
Takeda's seizure drug fails to meet main goal in late-stage studies	13:07
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome	12:55
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K	12:50
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	12:46
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	12:45
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	14.06.
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)	14.06.
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor	14.06.
Takeda Issues New Shares, Disposes of Treasury Shares Under Long-term Incentive Plan for Employees	11.06.
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts	11.06.
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K	11.06.
Takeda Pharmaceutical Prices Second Hybrid Bonds for 460 Billion Yen	10.06.
TAKEDA PHARMACEUTICAL : Form 6 K	10.06.
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K	07.06.
Former Takeda Employee Pleads Guilty to Defrauding Company	06.06.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Takeda Pharmaceutical Company Limited Deutsche Boerse AG

Aktien

A1CWZF

US8740602052

TKDA

Andere Sprachen

Filter